Clinical utility of ABCB1 single nucleotide polymorphism on tacrolimus dose requirements in Egyptian liver transplant patients

Egyptian Liver Journal

Table 6 Relation of ABCB1 genotype and C/D ratio, tacrolimus dose, and trough levels among the donor group 2 months and 3 months post transplantation (Mann–Whitney test)

ABCB1		CC	CT+TT	U test	P-value	Sig.
2nd month
Dose	Median (IQR)	0.05(0.04–0.08)	0.08(0.04–0.1)	−0.812	0.417	NS
Dose	Range	0.02–0.1	0.03–0.1	−0.812	0.417	NS
Trough level	Median (IQR)	6.65(5.9–8.1)	6.05(5.1–9.85)	−0.222	0.824	NS
Trough level	Range	2.2–10.6	3.8–14.6	−0.222	0.824	NS
C/D	Median (IQR)	108(82.5–167)	86(54.5–184.5)	−0.355	0.722	NS
C/D	Range	49–213	47–486	−0.355	0.722	NS
3rd month
Dose	Median (IQR)	0.05(0.03–0.06)	0.08(0.05–0.1)	−1.878	0.060	NS
Dose	Range	0.01–0.07	0.02–0.1	−1.878	0.060	NS
Trough level	Median (IQR)	5.4(2.1–8.2)	5.35(4.5–6.95)	−0.089	0.929	NS
Trough level	Range	1.4–9.1	3.2–7.4	−0.089	0.929	NS
C/D	Median (IQR)	142.5(71–150)	90.5(59.5–119.75)	−1.422	0.155	NS
C/D	Range	47–225	32–205	−1.422	0.155	NS

P-value >0.05, non-significant (NS); P-value <0.05, significant (S); P-value< 0.01, highly significant (HS)